APOL1肾病风险变异贯穿生命历程:综述
本综述聚焦载脂蛋白L1(APOL1)风险变异(RVs)相关肾病,从生命历程视角阐述其从宫内至成年的疾病过程,并讨论早期暴露于二次打击对长期结局的影响。APOL1相关肾病通常于青少年至青年期起病,携带RVs者进展至肾衰竭的风险高于无RVs的肾病患者;目前尚无确立的治疗方法。
要点
- APOL1风险变异是非洲裔人群肾病负担的重要遗传因素。
- APOL1相关肾病多于青少年至青年期起病,携带RVs者更易进展至肾衰竭。
- 环境暴露、感染等二次打击可影响APOL1风险变异的长期结局。
核心结论
- APOL1风险变异从宫内即可能影响疾病过程,并与环境暴露、感染和系统性疾病相互作用,改变全生命周期的健康结局。
- 携带APOL1风险变异的肾病患者比无风险变异者更可能进展至肾衰竭。
- 目前尚无针对APOL1相关肾病的确立治疗方法。
研究设计与样本
- 综述,聚焦APOL1相关疾病的生命历程视角。
- 讨论早期暴露于二次打击对长期结局的影响。
主要发现
- APOL1蛋白参与先天免疫,可能防御锥虫、HIV、沙门菌和利什曼病。
- 携带1个或多个风险变异可 contributor 于多种疾病过程,最早始于宫内,并可能被其他因素(二次打击)加重。
- APOL1相关肾病通常于青少年至青年期起病。
- 携带风险变异的个体比无APOL1风险变异的肾病患者更可能进展至肾衰竭。
- 正在开展的研究旨在阐明APOL1风险变异效应与供者和受者肾移植不良结局的关联。
临床怎么用
- 临床应关注非洲裔人群中APOL1风险变异携带者的肾病风险,尤其在青少年至青年期。
- 对携带APOL1风险变异的肾病患者,需认识到其进展至肾衰竭的风险更高。
- 目前尚无确立的APOL1相关肾病治疗方法,管理应聚焦于控制二次打击因素。
局限性
- 目前尚无针对APOL1相关肾病的确立治疗方法。
- 需要长期研究评估不同生命阶段APOL1风险变异相关的风险和保护因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two variant alleles of the gene apolipoprotein L1 (APOL1), known as risk variants (RVs), are a major contributor to kidney disease burden in those of African descent. The APOL1 protein contributes to innate immunity and may protect against Trypanosoma, HIV, Salmonella, and leishmaniasis. However, the effects of carrying 1 or more RVs contribute to a variety of disease processes starting as early as in utero and can be exacerbated by other factors (or "second hits"). Indeed, these genetic variations interact with environmental exposures, infections, and systemic disease to modify health outcomes across the life span. This review focuses on APOL1-associated diseases through the life-course perspective and discusses how early exposure to second hits can impact long-term outcomes. APOL1-related kidney disease typically presents in adolescents to young adults, and individuals harboring RVs are more likely to progress to kidney failure than are those with kidney disease who lack APOL-1 RVs. Ongoing research is aimed at elucidating the association of APOL1 RV effects with adverse donor and recipient kidney transplant outcomes. Unfortunately, there is currently no established treatment for APOL1-associated nephropathy. Long-term research is needed to evaluate the risk and protective factors associated with APOL1 RVs at different stages of life.
引用
- Itoku A, Isaac J, Wilson S, et al. APOL1 Nephropathy Risk Variants Through the Life Course: A Review. Am J Kidney Dis. 2024. PMID: 38341125. doi:10.1053/j.ajkd.2023.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。